RYTM: Rhythm Pharmaceuticals Inc

RYTM新闻

• 14:36 William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating
• 16:01 JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145
• 06:10 据此前报道，Rhythm Pharmaceuticals在日本推出IMCIVREE，作为获得批准的首个用于后天性下丘脑性肥胖的治疗药物，并得到3期TRANSCEND试验证实，可使BMI较安慰剂降低18.8%
• 06:10 Reported Earlier, Rhythm Pharmaceuticals Launches IMCIVREE In Japan As First Approved Therapy For Acquired Hypothalamic Obesity, Backed By Phase 3 TRANSCEND Trial Showing 18.8% Placebo-Adjusted BMI Reduction
• 15:00 Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know
• 10:34 HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130
• 14:56 RBC Capital维持对Rhythm Pharmaceuticals的“跑赢大盘”评级，将目标股价上调至159美元
• 14:56 RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159
• 14:45 过去 5 年持有 Rhythm Pharmaceuticals 股票，你本可以赚多少钱
• 14:45 Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
• 11:28 Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
• 23:46 Tracking Baker Brothers' Portfolio: Q2 2026 Update
• 19:51 Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
• 18:57 Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
• 08:35 Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM)
• 17:18 Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday? - Rhythm Pharmaceuticals (NASDAQ:RYTM)
• 12:25 Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
• 14:00 Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
• 14:00 Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release